OncoMed Pharmaceuticals, Inc.
OMED
OMED was delisted on the 22nd of April, 2019.
62 hedge funds and large institutions have $143M invested in OncoMed Pharmaceuticals, Inc. in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 26 increasing their positions, 21 reducing their positions, and 7 closing their positions.
523% more call options, than puts
Call options by funds: $1.84M | Put options by funds: $295K
24% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 21
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 63 → 62 (-1)
8% less capital invested
Capital invested by funds: $155M → $143M (-$12.3M)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$9.29M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$6.07M |
| 3 |
CIP
Convergence Investment Partners
Palm Beach Gardens,
Florida
|
+$1.67M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.52M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCI
Columbus Circle Investors
|
-$5.9M |
| 2 |
Primecap Management
Pasadena,
California
|
-$965K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$948K |
| 4 |
Invesco
Atlanta,
Georgia
|
-$892K |
| 5 |
Renaissance Technologies
New York
|
-$384K |
OMED Hedge Fund Activity: Q3 2014 in Review
62 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q3 2014, worth a combined $143M — down 7.9% from $155M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of OMED and 6 opened new positions — a net loss of 1 holder — while 21 trimmed existing stakes and 26 added.
The largest buyer was BVF Inc, adding an estimated $9.29M. The largest seller was Columbus Circle Investors, exiting entirely with an estimated $5.9M sold.
- 62 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q3 2014, down from 63 in Q2 2014.
- Funds reported $143M of OncoMed Pharmaceuticals, Inc. stock for Q3 2014, down 7.9% quarter-over-quarter.
- 6 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q3 2014 and 7 closed out, a net change of -1 holder.
- The largest OncoMed Pharmaceuticals, Inc. buyer in Q3 2014 was BVF Inc, an estimated $9.29M added.
- The largest OncoMed Pharmaceuticals, Inc. seller in Q3 2014 was Columbus Circle Investors, an estimated $5.9M sold.
Based on aggregated 13F filings for Q3 2014.